Description

BSE lists 10,20,000 new equity shares of Astal Laboratories Limited issued at Rs. 40/- on preferential basis via conversion of warrants, effective May 19, 2026.

Summary

BSE has listed 10,20,000 new equity shares of Astal Laboratories Limited (Scrip Code: 512600) issued at Rs. 40/- per share (face value Rs. 10/- at a premium of Rs. 30/-) to Non-Promoters on a preferential basis pursuant to conversion of warrants. These shares are permitted to trade on BSE with effect from Tuesday, May 19, 2026.

Key Points

  • 10,20,000 equity shares of Rs. 10/- each issued at a premium of Rs. 30/- per share (issue price Rs. 40/-)
  • Allotted to Non-Promoters on a preferential basis via conversion of warrants
  • New shares rank pari-passu with existing equity shares of the company
  • Distribution numbers: 41221933 to 42241932
  • ISIN: INE307N01014
  • All 10,20,000 new shares are subject to lock-in until 30 November 2026

Regulatory Changes

No broader regulatory changes. This is a company-specific listing notice under BSE’s Listing Operations for equity segment securities.

Compliance Requirements

  • Trading members are informed to note the new securities available for trading from May 19, 2026
  • Lock-in restrictions apply to all 10,20,000 newly listed shares (dist. nos. 41221933 to 42241932) until 30/11/2026; these shares cannot be traded during the lock-in period

Important Dates

  • Date of Allotment: 14 January 2026
  • Trading Effective Date: 19 May 2026
  • Lock-in Expiry: 30 November 2026

Impact Assessment

The listing adds 10,20,000 equity shares to Astal Laboratories Limited’s tradeable float, though the full quantity is locked in until end of November 2026, limiting immediate market impact. The preferential allotment at Rs. 40/- per share (conversion of warrants) expands the company’s equity base. Investors and trading members should note the lock-in constraints when assessing liquidity for this scrip.

Impact Justification

Routine listing of new equity shares from preferential allotment via warrant conversion; increases share capital but applies only to one company with lock-in restrictions on all new shares until November 2026.